

(FILE 'HOME' ENTERED AT 13:46:55 ON 15 MAR 2003)

FILE 'REGISTRY' ENTERED AT 13:47:02 ON 15 MAR 2003

L1 0 S DIMYCOLATE/CN
L2 0 S DIMYCOLATE

FILE 'CAPLUS, USPATFULL' ENTERED AT 13:49:04 ON 15 MAR 2003

L3 2506439 S PROTEIN OR ENZYME
L4 3790017 S WATER OR AQUEOUS
L5 602448 S ?TREHALOSE OR SUCROSE OR GLUCOSE OR MALTOSE OR GALATOSE OR
?
L6 18142 S L3 (P) L4 (P) L5
L7 3350 S (FORMULATION OR COMPOSITION) (P) L6
L8 454617 S ETHANOL OR ETHYL ALCOHOL OR ETHYLALCOHOL
L9 187 S L7 (P) L8
L10 20791 S PROTEIN (P) L8
L11 164 S PROTEIN (P) L9
L12 32 S ENZYME (P) L9
L13 1209 S (?TREHALOSE OR ?PYRANOSIDE) (P) L6
L14 258 S L13 (P) (COMPOSITION OR FORMULATION)
L15 19 S L14 (P) L8

Set Name Query

side by side

DB=DWPI; PLUR=YES; OP=ADJ

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
		result set	
<u>L21</u>	l10 and L20	2	<u>L21</u>
<u>L20</u>	l12 and L19	45	<u>L20</u>
<u>L19</u>	l8 and l6 and L18	162	<u>L19</u>
<u>L18</u>	\$10trehalose or \$10pyranoside	1825	<u>L18</u>
<u>L17</u>	l12 and L16	38	<u>L17</u>
<u>L16</u>	l10 and L15	162	<u>L16</u>
<u>L15</u>	L14 and l6	2482	<u>L15</u>
<u>L14</u>	l5 and l8 and L6	2482	<u>L14</u>
<u>L13</u>	l9 and L12	14	<u>L13</u>
<u>L12</u>	formulation or composition	684398	<u>L12</u>
<u>L11</u>	l9 and L10	1	<u>L11</u>
<u>L10</u>	ethanol or ethylalcohol or ethyl alcohol	45961	<u>L10</u>
<u>L9</u>	l7 and L8	57	<u>L9</u>
<u>L8</u>	protein or enzyme or factor or anitbody or anti body antigen or anti gen or hormone or cytokine or insulin	254098	<u>L8</u>
<u>L7</u>	l4 and l5 and L6	57	<u>L7</u>
<u>L6</u>	water or aqueous	1278147	<u>L6</u>
<u>L5</u>	trehalose or surcose or glucose or maltose or galactose or \$7pyranoside	27213	<u>L5</u>
<u>L4</u>	l1 or l2	1724	<u>L4</u>
<u>L3</u>	dis sol\$7 near2 (protein or enzyme or factor or anitbody or anti body antigen or anti gen or hormone or cytokine or insulin)	0	<u>L3</u>
<u>L2</u>	dissol\$7 near2 (protein or enzyme or factor or anitbody or anti body antigen or anti gen or hormone or cytokine or insulin)	1105	<u>L2</u>
<u>L1</u>	suspen\$7 near2 (protein or enzyme or factor or anitbody or anti body antigen or anti gen or hormone or cytokine or insulin)	653	<u>L1</u>

END OF SEARCH HISTORY

WEST

L17: Entry 21 of 38

File: DWPI

Apr 1, 1993

DERWENT-ACC-NO: 1993-117248

DERWENT-WEEK: 200048

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Emulsion contg. parathyroid hormone for admin. through nose - including glycyrrhizic acid (salt) acid and N-alkyl-thio-alkyl-substituted azetidinone or piperidinone as absorption promoter

INVENTOR: MANAKO, T; MORIMOTO, S ; SAITA, M ; SAKAKIBARA, H ; SHIMOZONO, Y ; SUGIMOTO, M ; YAMAMOTO, N

PRIORITY-DATA: 1991JP-0236193 (September 17, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9305805 A1	April 1, 1993	J	026	A61K037/24
JP 3090353 B2	September 18, 2000		010	A61K038/22
JP 05070367 A	March 23, 1993		010	A61K037/24
AU 9225843 A	April 27, 1993		000	A61K037/24
EP 610502 A1	August 17, 1994	E	016	A61K037/24
US 5407911 A	April 18, 1995		008	A61K037/24
AU 662168 B	August 24, 1995		000	A61K037/24
EP 610502 A4	February 28, 1996		000	A61K037/24
CA 2118655 C	August 19, 1997		000	A61K047/22
EP 610502 B1	July 22, 1998	E	000	A61K038/22
DE 69226370 E	August 27, 1998		000	A61K038/22
KR 129865 B1	April 9, 1998		000	A61K038/22

INT-CL (IPC): A61 K 9/00; A61 K 9/107; A61 K 9/72; A61 K 37/24; A61 K 38/22; A61 K 38/29; A61 K 47/22; A61 K 47/26; A61 K 47/28

ABSTRACTED-PUB-NO: EP 610502B

BASIC-ABSTRACT:

The emulsion contains (a) parathyroid hormone; (b) glycyrrhizic acid and azacycloalkane derivs. of formula (I) or their salts, as absorption promoter; and (c) water. In (I), R = alkyl; m = 2-4; n = 1-15; and when n = 1-3, R = 5-11C alkyl.

Pref. R1 = 10C alkyl; m = 3; and n = 2 ie. (I) is 1-(2-(decylthio)ethyl) azacyclo pentan-2-one. (IA). Compsn. contains 10-10,000 units parathyroid hormone/ml, 0.1-5 w/v glycyrrhizic acid, 0.1-10 w/v hormone (1-34), (I) etc.. A compsn. contg. human parathyroid hormone (1-34), glycyrrhizic acid or its salt, and (IA) is specifically claimed. Pref. pH is 5-7. It may contain glycerol, mannitol, NaCl, KCl, glucose etc., 0.02-2% w/v preservative e.g. p-hydroxy benzoate ester, chlorobutanol, phenyl ethyl alcohol, benzalkonium salt, sorbic acid etc.. The emulsion droplet size is 0.1-0.3 microns.

USE/ADVANTAGE - The emulsion is applied as nose drops or spray to the nose. The absorption is rapidly compared with absorption from powder and there is less lung damage. The emulsion is stable.

ABSTRACTED-PUB-NO:

US 5407911A EQUIVALENT-ABSTRACTS:

The emulsion contains (a) parathyroid hormone; (b) glycyrrhizic acid and azacycloalkane derivs. of formula (I) or their salts, as absorption promoter; and (c) water. In (I), R = alkyl; m = 2-4; n = 1-15; and when n = 1-3, R = 5-11C alkyl.

Pref. R1 = 10C alkyl; m = 3; and n = 2 ie. (I) is 1-(2-(decylthio)ethyl) azacyclo pentan-2-one. (IA). Compsn. contains 10-10,000 units parathyroid hormone/ml, 0.1-5 w/v glycyrrhizic acid, 0.1-10 w/v hormone (1-34), (I) etc.. A compsn. contg. human parathyroid hormone (1-34), glycyrrhizic acid or its salt, and (IA) is specifically claimed. Pref. pH is 5-7. It may contain glycerol, mannitol, NaCl, KCl, glucose etc., 0.02-2% w/v preservative e.g. p-hydroxy benzoate ester, chlorobutanol, phenyl ethyl alcohol, benzalkonium salt, sorbic acid etc.. The emulsion droplet size is 0.1-0.3 microns.

USE/ADVANTAGE - The emulsion is applied as nose drops or spray to the nose. The absorption is rapidly compared with absorption from powder and there is less lung damage. The emulsion is stable.

Parathyroid hormone (PH) contg. emulsion for nasal admin. comprises PH and at least one azacycloalkane deriv. of formula (I) as an absorption promoter, glycyrrhizic acid (GA) or its non toxic salt and water. In (I) R is alkyl pref. 10C alkyl; m is 2-4 pref. 3 and n is 1-5 pref. 2 provided that R is 5-11C alkyl when n is 1-3. Pref. the compsn. comprises PH(1-34), GA or its non toxic salt and 1-(2-(decylthio) ethyl)azacyclopentan-2-one.

USE/ADVANTAGE - PH is a peptide hormone having serum calcium elevating activity and being used as a diagnostic agent for hypoparathyroidism. The PH compsn. has improved stability over prior art compsns. PH is absorbed safely and efficiently by spraying into the nasal cavity. The problems such as pain and anguish encountered with admin. by injection are avoided.

WO 9305805A

WEST [Generate Collection](#) [Print](#)

L17: Entry 37 of 38

File: DWPI

Oct 14, 1976

DERWENT-ACC-NO: 1976-89578X

DERWENT-WEEK: 197648

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Detergent compsn. for foods - contg. a sucrose fatty acid ester, protein and peptide

PRIORITY-DATA: 1975JP-0042506 (April 7, 1975)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 51116806 A	October 14, 1976		000	

INT-CL (IPC): C11D 1/66; C11D 3/37; C11D 10/02

ABSTRACTED-PUB-NO: JP 51116806A

BASIC-ABSTRACT:

Sucrose fatty acid water system liq. detergent compsn. for foods comprises (a) a sucrose fatty acid ester (which consist of (un)satd. fatty acids of 8-20C; the content of monoester is pref. 40-80E%), (b) protein (pref. soluble animal or vegetable protein), and (c) peptide (animal or vegetable protein hydrolysate of <10,000 mol. wt.) and its salt with sodium, potassium, triethanolamine, etc. as essential components, and further adding a suitable solvent (alcohol such as ethanol, propylene glycol or glycerin or water), a soluble stabiliser (saccharide such as sucrose, glucose, sorbitol, dextrin, raffinose, trehalose, etc.) preserving agent, perfume, colouring agent, etc. to it. The washing power and foaming power of sucrose fatty acid ester can be further improved. Also touch and mild feeling to skin can be improved.

WEST [Generate Collection](#) [Print](#)

L17: Entry 36 of 38

File: DWPI

Apr 7, 1981

DERWENT-ACC-NO: 1982-03565E

DERWENT-WEEK: 198202

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Dietary compsn. for use in protein deficiency - protein hydrolysis prod.
glucose, ethanol, peppermint extract, di:sodium phosphate and saccharin

INVENTOR: CHAPLYGINA, Z A; HLEBNIKOVA, I M ; SABASHNIKO, G M

PRIORITY-DATA: 1975SU-2172881 (September 19, 1975)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
SU 818619 B	April 7, 1981		002	

INT-CL (IPC): A61K 37/18

ABSTRACTED-PUB-NO: SU 818619B

BASIC-ABSTRACT:

The compsn. for treatment of patients with protein deficiency due to the pathological processes contains (in wt. %): protein hydrolysate (I) 20-25, glucose 20-30, ethanol 4-6, peppermint extract 1.0-1.4, disodium phosphate 0.08-0.12, saccharin 0.03-0.05 and water.

The compsn. is 5 times more potent than an agent consisting of I, glucose and ethanol only.

Protein hydrolysate is passed through an ion exchanger and spray dried at 90-120 deg.C, and powder dissolved in water at 60-70 deg.C. to give soln. contg. 20-25% of amino acids which is mixed with a soln. of glucose, disodium phosphate and saccharin, cooled to room temp. and ethanol and the peppermint extract are added. The final volume is adjusted to the correct content of nitrogen. The soln. is clarified and sterilised by filtration for storage. (2pp)